Dexamethasone Cipecilate

地塞米松培酯

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NameDexamethasone Cipecilate
Drug Alias Namecipecilato de dexametasonadexamethasoni cipecilasErizasNS-126NS-126M +[10] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonists
TargetsGlucocorticoid receptor
Therapy Area/IndicationsDiabetic macular oedemaChemotherapy-induced nausea and vomitingSolid tumours +[86] 
Global Approved IndicationsRhinitis, Allergic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2009/10/16
Country/TerritoryCzechiaCanadaUnited States +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNippon Shinyaku Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteH Lee Moffitt Cancer Center & Research InstituteNational Cancer Institute +[7] 
Inactive CompaniesEhime University Graduate School Of MedicineJanssen-Ortho Inc., CanadaNational Institutes Of Health Clinical Center (Cc) +[62] 
Active IndicationsSolid tumoursRhinitis, Allergic, SeasonalRhinitis, Allergic +[7] 
Inactive IndicationsDiabetic macular oedemaChemotherapy-induced nausea and vomitingDrug-Related Side Effects and Adverse Reactions +[79] 

Other Information

ATC CodeA01AC02C05AA09D07AB19 +[11] 
Related LinksDrugBankKEGG